Results 141 to 150 of about 108,576 (328)
Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma +9 more
wiley +1 more source
Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou +6 more
wiley +1 more source
A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen [PDF]
Rose A. Maciewicz, David J. Etherington
openalex +1 more source
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao +4 more
wiley +1 more source
Leaf senescence is a developmental process that allows nutrients to be remobilized and transported to sink organs. Previously, papain-like cysteine proteases (PLCPs) have been found to be highly expressed during leaf senescence in different plant species.
Igor A. Schepetkin, Andreas M. Fischer
doaj +1 more source
Cathepsin B‐sensitive peptide–adjuvant conjugates are designed, synthesized, and evaluated to deliver an antigenic peptid and an adjuvant targeting Toll‐like receptors 7 and 8 (TLR7/8) to antigen presenting cells. The adjuvant is released by cathepsin B resulting in antigen presentation and TLR mediated T cell activation.
Marjolein M. E. Isendoorn +6 more
wiley +1 more source
Human proteoglycan testican‐1 inhibits the lysosomal cysteine protease cathepsin L [PDF]
Jeffrey P. Bocock +3 more
openalex +1 more source
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Objective To investigate the secretion of lysosomal Pro ⁃ cathepsin L and its contribution to neuronal apoptosis upon lipopolysaccharide (LPS) stimulation.
Hui ZHANG +4 more
doaj

